

S30. New approaches in anxiety states – panic and phobic disorders	64s
S31. Personality disorders	66s
S32. Assessment of quality of life in psychiatry	68s
S33. Psychosomatic disorders	70s
S34. Alzheimer's disease	72s
S35. Neurasthenia	74s
S36. Panic, anxiety and its treatment	76s
S37. New strategies with antiepileptics	78s
S38. Long-term studies in psychiatry	80s
S39. Neuroleptic drugs	83s
S40. Anxiolytic drugs	86s
S41. Biological and clinical changes in the course of mental disorders	88s
S42. Affective disorders: biological and social aspects	90s
S43. The national scientific psychiatric associations: their role in the development of psychiatry	93s
S44. Mental Health Services	95s
S45. Psychogeriatrics	98s
S46. Community psychiatry in post-socialist countries	101s
S47. Child psychiatry	103s
S48. Schizophrenia: neurobiology, neuropsychology and clinical symptoms	105s
S49. Eastern Europe: psychiatry and political changes	108s
S50. Structured diagnostic interviews	111s
S51. Depressive spectrum disorders	113s
S52. Assessment of treatment of psychiatric disorders	115s
S53. Consultation-liaison psychiatry	117s
S54. Expert judgement on the use of psychotherapeutic medication	119s
S55. Mental health in mental retardation	121s
S56. Suicide and aggression	123s
S57. Computers in mental health	126s
ICD-10. Postgraduate training course	128s
Satellite symposium. Zopiclone: from clinical practice to quality of life	
1. Zopiclone, sleep and health-related quality of life	133s
2. Zopiclone, a continuing contribution to the management of sleep disorders	136s
Satellite Symposium. Interest of tianeptine in the treatment of mood disturbances and mixed anxious depressed disorders	139s
1. Antidepressant effect of tianeptine: the paradox between clinical and neurochemical data ...	140s
2. New outlooks with tianeptine in the treatment of mood disturbances	142s
POSTERS	
Diagnostic systems. Education. Information. Mentally ill/society	145s
Psychoses:	
– treatment	153s
– diagnostics/characteristics	157s
– basic (etiology and investigations)	161s
Depression, mood disorders:	
– treatment	163s
– diagnoses/characteristics	169s
– basic (etiology and investigations)	172s
Laboratory diagnoses: basic research	175s
Psychogeriatrics	178s
Personality traits/disorders. Sleep disorders	180s
Child psychiatry	183s
Abuse/craving:	
– treatment	184s
– diagnoses	187s
– basic	191s
Drugs: intoxication, safety, adverse events, pharmacogenetics	192s
Liaison psychiatry	196s
Sex	199s
Psychotherapy. Non-pharmacological treatment	200s
Mental retardation	202s
<i>Instructions to Authors</i>	203s

Cited/abstracted in: Biological Abstracts/Biosis, CNRS/Pascal, Excerpta Medica/EMbase, Psychological Abstracts

**SEROXAT®
PAROXETINE**

Novo Nordisk AIS

Novo Nordisk Park
2760 Måløv
Denmark

Tel. + 45 44 44 88 88
Fax + 45 44 42 45 47

